药明巨诺（港交所代码：2126）是一家独立的、专注于开发、生产及商业化细胞免疫治疗产品的创新型生物科技公司。创建于2016年，药明巨诺致力于以创新为先导，成为细胞免疫治疗引领者。药明巨诺已打造了细胞免疫疗法的技术与产品开发平台，以及涵盖血液及实体肿瘤、极具潜力的产品管线，以期为中国乃至全球患者带来治愈的希望，并促进中国细胞免疫治疗产业的健康规范发展。
JW Therapeutics (HKEx: 2126) is an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Founded in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The company has built a world-class platform for technology and product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic malignancies and solid tumors, to bring the hope of a cure for Chinese and global patients, and to lead the healthy and standardized development of China’s cell immunotherapy industry.